Baird analyst Mark Marcon extended his bullish Fresh Pick designation on Health Equity through March 24 which is right after they posts Q4 results which he believes will be positive. He said the company is levered to higher rates which will benefit earnings over the next few years, particularly if rates remain elevated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HQY:
- Innovative Benefits Plan Demonstrates How HSAs can Further Pay Equity
- HealthEquity price target raised to $85 from $75 at Raymond James
- HealthEquity price target raised to $94 from $89 at Guggenheim
- HealthEquity sees FY24 revenue $950M-$970M, consensus $948.4M
- HealthEquity raises FY23 EPS view to $1.26-$1.35 from $1.23-$1.32